Specifically, evidence coming from the combined analysis of the Seattle Kidney Study and the Clinical Phenotyping and Resource Biobank Study pointed toward an increased risk of mortality with higher serum galectin-3 levels among patients with pre-dialysis chronic kidney disease [24]. The gene discussed is LGALS3; the disease is chronic kidney disease.